ADC Therapeutics' restructuring extends cash runway to 2029, but Zynlonta safety/regulatory risks loom. Click here to read ...
Ascent Industries (ACNT) shifts to specialty chemicals; Q2 FY26 sales +38% and EBITDA margin 5.7%, but cash burn persists.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results